GO:0098983 symmetric, GABA-ergic, inhibitory synapse: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0098983 describes a neuron-to-neuron synapse that uses GABA as its neurotransmitter, lacks an electron-dense postsynaptic specialization, and produces inhibitory postsynaptic potentials.
• These synapses are defined ultrastructurally by symmetric membrane specializations and are often identified by the presence of GABA-synthesizing enzymes and vesicular GABA transporters.
• Key proteins enriched at symmetric, GABA-ergic synapses include GAD65/67, VGAT, GABA-A receptor subunits, GABA-B receptor subunits, and gephyrin.
• Dysfunction of GABA-ergic inhibitory synapses is implicated in epilepsy, anxiety disorders, and neurodegenerative conditions such as Huntington's disease.
• CRISPR-based knockout, point-mutation, and knock-in models enable causal testing of genes that build and regulate symmetric, GABA-ergic synapses.
• Understanding GO:0098983 requires combining ultrastructural imaging, electrophysiology, and molecular profiling of GABA-ergic components.
Description
The Gene Ontology cellular component term GO:0098983, symmetric, GABA-ergic, inhibitory synapse, defines a specialized neuron-to-neuron contact that releases gamma-aminobutyric acid (GABA) and generates inhibitory postsynaptic potentials. Unlike excitatory synapses, these contacts lack a prominent electron-dense postsynaptic specialization, which gives them a symmetric appearance in electron micrographs. This ultrastructural signature is a key criterion for identifying inhibitory synapses in brain tissue. Researchers study GO:0098983 because GABA-ergic inhibition shapes network oscillations, prevents runaway excitation, and is disrupted in numerous neurological and psychiatric disorders. The term is also central to interpreting connectomic and electrophysiological data, where symmetric synapses are mapped onto specific interneuron populations. In this article, we integrate the QuickGO definition with verified PubMed literature to describe the components, assembly, regulation, and research methods relevant to GO:0098983.
symmetric, GABA-ergic, inhibitory synapse At A Glance
| GO ID | GO:0098983 |
|---|---|
| GO term | symmetric, GABA-ergic, inhibitory synapse |
| Ontology | cellular_component |
| Synonym | none |
| Major function | Mediates inhibitory neurotransmission via GABA release and postsynaptic receptor activation |
| Ultrastructure | Symmetric membrane specializations with no prominent electron-dense postsynaptic density |
| Key transmitters | GABA |
| Typical markers | GAD65/67, VGAT, GABA-A and GABA-B receptor subunits, gephyrin |
| Physiological outcome | Inhibitory postsynaptic potentials |
What Is GO:0098983?
GO:0098983 is a cellular component term describing a neuron-to-neuron synapse that uses GABA as a neurotransmitter, lacks an electron-dense postsynaptic specialization, and whose activity results in inhibitory postsynaptic potentials. In practice, such synapses are recognized by symmetric membrane thickenings, presynaptic GABA-synthesizing enzymes, and postsynaptic GABA receptors.
Why Is symmetric, GABA-ergic, inhibitory synapse Important in Cell Biology?
Symmetric, GABA-ergic synapses are the primary substrate for fast and slow inhibition in the mammalian brain, and their dysfunction is linked to epilepsy, anxiety, and neurodegenerative disease. Because these synapses are defined by both ultrastructural and molecular features, they serve as a convergence point for connectomics, electrophysiology, and molecular neuroscience.
• They generate inhibitory postsynaptic potentials that control neuronal excitability.
• They are identified by symmetric ultrastructure, distinguishing them from excitatory synapses.
• They are enriched in GABA-synthesizing enzymes such as GAD65/67.
• They express vesicular GABA transporter VGAT for loading GABA into synaptic vesicles.
• Postsynaptic GABA-A and GABA-B receptors mediate fast and slow inhibition.
• Gephyrin scaffolds GABA-A and glycine receptors at inhibitory postsynapses.
• Loss of symmetric synapses is observed in epilepsy models and human tissue.
• They are targets for anxiolytic, anticonvulsant, and anesthetic drugs.
• They are studied in hypothalamic, amygdalar, hippocampal, and brainstem circuits.
• CRISPR models allow causal testing of genes required for their assembly and function.
What Happens During symmetric, GABA-ergic, inhibitory synapse?
Presynaptic GABA synthesis and vesicle loading
In simple terms: The presynaptic neuron makes GABA and packs it into small bubbles called vesicles.
At symmetric, GABA-ergic synapses, the presynaptic terminal expresses glutamic acid decarboxylase (GAD65/67), which synthesizes GABA from glutamate. The vesicular GABA transporter (VGAT) then loads GABA into synaptic vesicles. These presynaptic features are used to identify GABA-ergic terminals in ultrastructural studies.
Calcium-dependent GABA release
In simple terms: When the presynaptic neuron fires, calcium enters and triggers the vesicles to release GABA.
Action potentials arriving at the presynaptic terminal open voltage-gated calcium channels, raising intracellular calcium and triggering fusion of GABA-containing vesicles with the plasma membrane. The released GABA diffuses across the synaptic cleft to act on postsynaptic receptors.
Postsynaptic GABA receptor activation
In simple terms: GABA binds to receptors on the postsynaptic side, opening ion channels that quiet the neuron.
GABA binds to postsynaptic GABA-A receptors, which are ligand-gated chloride channels, and to GABA-B receptors, which are G-protein-coupled receptors. GABA-A receptor activation typically causes chloride influx and hyperpolarization, producing inhibitory postsynaptic potentials. GABA-B receptors can also activate potassium channels and inhibit calcium channels, contributing to slow inhibition.
Symmetric ultrastructure and lack of postsynaptic density
In simple terms: These synapses look symmetric under the microscope because the postsynaptic side lacks a thick dark patch.
Electron microscopy shows that symmetric, GABA-ergic synapses have pre- and postsynaptic membrane thickenings of similar thickness and lack an electron-dense postsynaptic specialization. This contrasts with asymmetric excitatory synapses, which have a prominent postsynaptic density. The symmetric appearance is a key diagnostic feature for identifying inhibitory synapses in tissue sections.
Scaffolding and receptor clustering
In simple terms: Scaffold proteins hold GABA receptors in place at the synapse.
The scaffolding protein gephyrin clusters GABA-A and glycine receptors at inhibitory postsynaptic sites. Other proteins, including collybistin and neuroligin-2, contribute to inhibitory synapse assembly and maintenance. These molecular components ensure efficient inhibitory transmission.
Key Genes Involved in GO:0098983 symmetric, GABA-ergic, inhibitory synapse
The following genes and proteins are central to the structure, function, and regulation of symmetric, GABA-ergic, inhibitory synapses.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GAD1 | Synthesizes GABA from glutamate | Marker of GABA-ergic presynaptic terminals |
| GAD2 | Synthesizes GABA from glutamate | Marker of GABA-ergic presynaptic terminals |
| SLC32A1 (VGAT) | Loads GABA into synaptic vesicles | Presynaptic marker for inhibitory synapses |
| GABRA1 | GABA-A receptor alpha1 subunit | Mediates fast inhibitory postsynaptic potentials |
| GABRB2 | GABA-A receptor beta2 subunit | Mediates fast inhibitory postsynaptic potentials |
| GABRG2 | GABA-A receptor gamma2 subunit | Mediates fast inhibitory postsynaptic potentials |
| GABBR1 | GABA-B receptor subunit 1 | Mediates slow inhibitory postsynaptic potentials |
| GABBR2 | GABA-B receptor subunit 2 | Mediates slow inhibitory postsynaptic potentials |
| GPHN | Scaffolding protein at inhibitory postsynapse | Clusters GABA-A receptors |
| ARHGEF9 | Collybistin, regulates gephyrin clustering | Inhibitory synapse assembly |
| NLGN2 | Postsynaptic adhesion molecule | Inhibitory synapse specification |
| PVALB | Calcium-binding protein in GABA-ergic interneurons | Marker of specific inhibitory interneuron subtypes |
| SST | Neuropeptide in GABA-ergic interneurons | Marker of specific inhibitory interneuron subtypes |
| VIP | Neuropeptide in GABA-ergic interneurons | Marker of specific inhibitory interneuron subtypes |
| CCK | Neuropeptide in GABA-ergic interneurons | Marker of specific inhibitory interneuron subtypes |
| TRH | Thyrotropin-releasing hormone | Co-expressed in some GABA-ergic neurons |
| TH | Tyrosine hydroxylase | Catecholaminergic neurons receiving GABA-ergic input |
How Is symmetric, GABA-ergic, inhibitory synapse Regulated?
The formation and function of symmetric, GABA-ergic synapses are regulated by neuronal activity, neuromodulators, and intracellular signaling pathways. For example, GABA-B receptor activation can modulate presynaptic GABA release and postsynaptic excitability. In the hypothalamus, GABA-ergic innervation of TRH-synthesizing neurons is sensitive to hormonal and metabolic state. In the hippocampus and striatum, hypoglycemia alters the distribution of neuroactive amino acids, including GABA, indicating metabolic regulation of inhibitory transmission. These findings highlight that GO:0098983 synapses are dynamic structures whose molecular composition and efficacy are tuned by physiological context.
symmetric, GABA-ergic, inhibitory synapse and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GABRA1 | Epilepsy | Knock-in mouse with patient mutation |
| GABRB2 | Epilepsy | Knockout or point-mutation cell model |
| GPHN | Hyperekplexia, epilepsy | Knockout mouse and iPSC-derived neurons |
| GAD1 | Schizophrenia, epilepsy | Knockout and overexpression models |
| SLC32A1 | Epilepsy | Knockout mouse and cell-based assays |
Epilepsy and seizure disorders
Loss or dysfunction of symmetric, GABA-ergic synapses reduces inhibition and can lead to seizures. In the dentate gyrus, vulnerable interneuron populations form symmetric synapses onto granule cells, and their loss is associated with hyperexcitability. Mutations in GABA-A receptor subunits and gephyrin have been linked to epilepsy syndromes.
Anxiety and psychiatric disorders
GABA-ergic inhibition in the amygdala and periaqueductal gray is critical for fear and anxiety regulation. Alterations in GABA-A and GABA-B receptor expression at symmetric synapses are observed in animal models of anxiety. These synapses are targets for anxiolytic drugs such as benzodiazepines.
Neurodegeneration and metabolic stress
Metabolic insults such as hypoglycemia disrupt GABA distribution in the hippocampus and striatum, potentially impairing inhibitory synapse function. In neurodegenerative conditions, loss of GABA-ergic interneurons and their symmetric synapses contributes to network dysfunction. Understanding these changes may guide neuroprotective strategies.
From symmetric, GABA-ergic, inhibitory synapse-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GAD67 reduce GABA-ergic synapse density? | GAD1 knockout mouse or CRISPR KO cell line |
| Does a patient GABA-A receptor mutation impair inhibitory currents? | Point-mutation knock-in mouse or iPSC-derived neurons |
| Can gephyrin clustering be restored by gene replacement? | Knock-in of wild-type GPHN in KO background |
| Where is VGAT localized in live neurons? | Tagged knock-in of SLC32A1 with fluorescent protein |
| Does overexpression of NLGN2 increase inhibitory synapse number? | Overexpression in cultured neurons |
| Which genes regulate symmetric synapse formation? | CRISPR library screening in primary neurons |
How to Study the symmetric, GABA-ergic, inhibitory synapse Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Electron microscopy | Ultrastructure and symmetry of synapses | Identification of symmetric synapses |
| Immunogold labeling | Subcellular localization of GABA or GAD | Confirmation of GABA-ergic terminals |
| Patch-clamp electrophysiology | Inhibitory postsynaptic currents | Functional assessment of GABA-A/B receptors |
| Immunohistochemistry | Protein localization and co-localization | Synapse density and composition |
| Confocal microscopy | Fluorescence intensity and colocalization | Quantification of synaptic puncta |
| RNA sequencing | Gene expression profiles | Identification of GABA-ergic neuron markers |
| Proteomics | Protein composition of synaptosomes | Discovery of novel synaptic proteins |
| CRISPR screening | Genes required for synapse formation | Functional genomics of inhibitory synapses |
Electron microscopy and ultrastructural analysis
Electron microscopy is the gold standard for identifying symmetric, GABA-ergic synapses based on membrane specializations. Immunogold labeling for GABA or GAD can confirm the GABA-ergic nature of the terminal. Quantitative analysis of synapse number and morphology is used to compare conditions.
Electrophysiology
Patch-clamp recordings measure inhibitory postsynaptic currents (IPSCs) mediated by GABA-A and GABA-B receptors. Miniature IPSCs reflect spontaneous vesicle release, while evoked IPSCs assess action-potential-dependent transmission. These methods directly test the functional output of GO:0098983 synapses.
Immunohistochemistry and confocal imaging
Antibodies against GAD65/67, VGAT, GABA-A receptor subunits, and gephyrin are used to visualize inhibitory synapses. Co-localization of presynaptic and postsynaptic markers indicates putative symmetric synapses. Confocal and super-resolution microscopy allow quantification of synapse density and size.
Transcriptomics and proteomics
RNA sequencing and proteomics can profile gene expression in GABA-ergic neurons or synaptosomes. These approaches identify novel components and regulators of symmetric synapses. Bioinformatics analysis of public datasets can reveal disease-associated changes.
How CRISPR Can Be Used to Study GO:0098983 symmetric, GABA-ergic, inhibitory synapse
Knockout
CRISPR knockout of genes such as GAD1, SLC32A1, or GPHN can abolish GABA synthesis, vesicle loading, or receptor clustering, respectively. These models are used to test the requirement of specific genes for symmetric synapse formation and function. Knockout cell lines and mice are valuable for electrophysiological and imaging studies.
Point Mutation
Point mutations in GABA-A receptor subunits (e.g., GABRA1, GABRB2) identified in patients can be introduced into cell lines or mice to study effects on receptor trafficking and inhibitory currents. Such models help establish causality between specific variants and synaptic dysfunction.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) into endogenous loci such as GAD1 or SLC32A1 allows real-time visualization of GABA-ergic neurons and synapses. Knock-in of wild-type genes into knockout backgrounds can rescue phenotypes and confirm specificity.
Overexpression
Overexpression of synaptic organizers such as NLGN2 or gephyrin can increase inhibitory synapse number or strength in cultured neurons. These models are useful for gain-of-function studies and for testing therapeutic strategies.
How EDITGENE Supports symmetric, GABA-ergic, inhibitory synapse Research
Researchers studying symmetric, GABA-ergic, inhibitory synapse-related genes often need to determine whether a candidate gene is causally involved in synapse formation, maintenance, or function. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous testing of gene function in the context of GO:0098983.
Contact EDITGENE today to design your custom CRISPR model for symmetric, GABA-ergic, inhibitory synapse research.
Frequently Asked Questions About symmetric, GABA-ergic, inhibitory synapse
What is GO:0098983?
GO:0098983 is a Gene Ontology cellular component term for a neuron-to-neuron synapse that uses GABA as a neurotransmitter, lacks an electron-dense postsynaptic specialization, and produces inhibitory postsynaptic potentials.
What genes are involved in symmetric, GABA-ergic, inhibitory synapses?
Key genes include GAD1, GAD2, SLC32A1 (VGAT), GABRA1, GABRB2, GABRG2, GABBR1, GABBR2, GPHN, ARHGEF9, and NLGN2.
How are symmetric synapses identified?
They are identified by electron microscopy as having symmetric membrane thickenings and no prominent postsynaptic density, often with GABA or GAD immunoreactivity.
What is the role of gephyrin at inhibitory synapses?
Gephyrin is a scaffolding protein that clusters GABA-A and glycine receptors at inhibitory postsynaptic sites.
Which diseases are linked to GABA-ergic synapse dysfunction?
Epilepsy, anxiety disorders, and neurodegenerative conditions such as Huntington's disease have been associated with impaired GABA-ergic inhibition.
How can CRISPR be used to study GO:0098983?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes required for symmetric synapse formation and function.
What is the difference between symmetric and asymmetric synapses?
Symmetric synapses are typically inhibitory and GABA-ergic, while asymmetric synapses are excitatory and glutamatergic, with a prominent postsynaptic density.
What neurotransmitters are used at GO:0098983 synapses?
GABA is the primary neurotransmitter at these synapses.
What electrophysiological signature do these synapses produce?
They produce inhibitory postsynaptic potentials (IPSPs) and inhibitory postsynaptic currents (IPSCs).
Where in the brain are symmetric, GABA-ergic synapses found?
They are found throughout the brain, including the hypothalamus, amygdala, hippocampus, striatum, and brainstem.
Conclusion
GO:0098983 captures the essential features of symmetric, GABA-ergic, inhibitory synapses: GABA release, symmetric ultrastructure, and inhibitory postsynaptic potentials. These synapses are fundamental to brain function and are implicated in epilepsy, anxiety, and neurodegeneration. By combining ultrastructural, electrophysiological, and CRISPR-based approaches, researchers can dissect the molecular mechanisms that build and regulate these synapses. EDITGENE offers the tools needed to accelerate this research.
References
- 1. Fekete C et al.. 2002. GABA-ergic innervation of thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus of the rat.. Brain Res 957(2):251-8 PMID: 12445967
- 2. Milner TA et al.. 1989. Adrenergic neurons in the rostral ventrolateral medulla: ultrastructure and synaptic relations with other transmitter-identified neurons.. Prog Brain Res 81:29-47 PMID: 2694222
- 4. Smith Y et al.. 1998. Cat intraamygdaloid inhibitory network: ultrastructural organization of parvalbumin-immunoreactive elements.. J Comp Neurol 391(2):164-79 PMID: 9518267
- 5. Gundersen V et al.. 2001. Redistribution of neuroactive amino acids in hippocampus and striatum during hypoglycemia: a quantitative immunogold study.. J Cereb Blood Flow Metab 21(1):41-51 PMID: 11149667
- 6. Buckmaster PS et al.. 2002. Axon arbors and synaptic connections of a vulnerable population of interneurons in the dentate gyrus in vivo.. J Comp Neurol 445(4):360-73 PMID: 11920713
- 8. Barbaresi P. 2007. Cellular and subcellular localization of the GABA(B) receptor 1a/b subunit in the rat periaqueductal gray matter.. J Comp Neurol 505(5):478-92 PMID: 17924569
